• Confirmed solid tumour diagnosis: Supporting selection of potential therapeutic agents following cancer diagnosis.
• Treatment planning support: Comparing tumour cell response to selected chemotherapy drugs or natural agents.
• Relapsed or progressive disease: Identifying alternative treatment options where prior therapies have been ineffective.
• Multiple treatment options being considered: Supporting comparison of potential therapeutic approaches.
• Integrative treatment discussions: Informing consideration of conventional and adjunctive strategies.

Overview

chemo-scale™ 30 substances evaluates how tumour-derived cells respond when exposed to a selected group of chemotherapeutic drugs or natural agents. This focused panel enables comparison of how tumour cells react to different treatment exposures under laboratory conditions.

Assessing sensitivity at the cellular level may help identify therapies that appear more likely to be effective and highlight options that may be less suitable. This can support treatment planning where several therapeutic approaches are being considered.

Results are reviewed alongside tumour type, stage, previous treatments and overall oncology care decisions. Considering chemosensitivity findings within this wider clinical picture can help guide more individualised therapy selection.